Pharming Group announces third quarter 2026 revenues above market expectations
Key Highlights
- ➤Q3 revenue approximately US$117.6 million, up 21% year-on-year
- ➤2026 revenue guidance tightened to US$380 million-US$390 million
- ➤2026 operating expense guidance lowered to US$310 million-US$315 million
- ➤RUCONEST revenue US$93.8 million, up 14% year-on-year
- ➤Joenja revenue US$23.8 million, up 58% year-on-year
* Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 * Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025 * Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million * Full third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDT Leiden, the Netherlands, October 22, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announces preliminary, unaudited revenue and select financial information for the three months ended September 30, 2026. Pharming will report its full preliminary (unaudited) financial results for the third quarter 2026 and provide a business update on October 27, 2026, brought forward from November 5, 2026 following results indicating revenue above and total operating expenses below analyst consensus.
Get started
Create a free account to read the full story.